Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Invivo Therapeutics …
In biotech, we are dealing with heavily catalyst-driven stocks, triggered by binary events such as FDA decisions and clinical data readouts. Case in …
As two biotech companies continue announce pipeline progressions, for better or worse, analysts weigh in on Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Invivo Therapeutics …
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) shares rose 13% this morning after the company announced that it received conditional FDA approval of a study protocol …
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced that a fourth patient has been enrolled in the company’s ongoing pilot trial of its investigational Neuro- …
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced promotions for two members of its management team. Christopher McNulty has been appointed as Senior Vice President, Business …
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) reported financial results for the quarter ended June 30, 2015. Mark Perrin, Chief Executive Officer and Chairman, said, …
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second …
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced that Rutgers New Jersey Medical School in Newark, NJ has been added as a clinical site in …
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced that the company has been added to the Russell Global, Russell 3000®, Russell 2000®, and Russell Microcap …
